These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 35998303)

  • 1. Long-Term Efficacy and Safety of Luspatercept for Anemia Treatment in Patients With Lower-Risk Myelodysplastic Syndromes: The Phase II PACE-MDS Study.
    Platzbecker U; Götze KS; Kiewe P; Germing U; Mayer K; Radsak M; Wolff T; Chromik J; Sockel K; Oelschlägel U; Haase D; Illmer T; Al-Ali HK; Silling G; Reynolds JG; Zhang X; Attie KM; Shetty JK; Giagounidis A
    J Clin Oncol; 2022 Nov; 40(33):3800-3807. PubMed ID: 35998303
    [No Abstract]   [Full Text] [Related]  

  • 2. Luspatercept for the treatment of anaemia in patients with lower-risk myelodysplastic syndromes (PACE-MDS): a multicentre, open-label phase 2 dose-finding study with long-term extension study.
    Platzbecker U; Germing U; Götze KS; Kiewe P; Mayer K; Chromik J; Radsak M; Wolff T; Zhang X; Laadem A; Sherman ML; Attie KM; Giagounidis A
    Lancet Oncol; 2017 Oct; 18(10):1338-1347. PubMed ID: 28870615
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Luspatercept in combination with recombinant erythropoietin in patients with myelodysplastic syndrome with ring sideroblasts: Stimulating early and late-stage erythropoiesis.
    Fattizzo B; Versino F; Bortolotti M; Rizzo L; Riva M; Barcellini W
    Eur J Haematol; 2023 May; 110(5):571-574. PubMed ID: 36727250
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Experience with luspatercept therapy in patients with transfusion-dependent low-risk myelodysplastic syndromes in real-world clinical practice: exploring the positive effect of combination with erythropoietin alfa.
    Jonasova A; Sotakova S; Belohlavkova P; Minarik L; Stopka T; Jonas JJ; Aghova T; Zemanova Z
    Front Oncol; 2024; 14():1398331. PubMed ID: 39416466
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Development of luspatercept to treat ineffective erythropoiesis.
    Kubasch AS; Fenaux P; Platzbecker U
    Blood Adv; 2021 Mar; 5(5):1565-1575. PubMed ID: 33687432
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Luspatercept in Myelodysplastic Syndromes: Who and When?
    Komrokji RS
    Hematol Oncol Clin North Am; 2020 Apr; 34(2):393-400. PubMed ID: 32089218
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of refractory or relapsed myelodysplastic neoplasms with luspatercept: a multicenter Chinese study.
    Zhang Z; Hu Q; Tang X; Zhang M; Jia J; Shi H; Ding X; Yang C; Chen M; Han B
    Ann Hematol; 2023 Nov; 102(11):3039-3047. PubMed ID: 37682325
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Luspatercept in low-risk myelodysplastic syndromes: a paradigm shift in treatment strategies.
    Molica M; Rossi M
    Expert Opin Biol Ther; 2024 Apr; 24(4):233-241. PubMed ID: 38555469
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The prognostic value of serum erythropoietin in patients with lower-risk myelodysplastic syndromes: a review of the literature and expert opinion.
    Park S; Kelaidi C; Meunier M; Casadevall N; Gerds AT; Platzbecker U
    Ann Hematol; 2020 Jan; 99(1):7-19. PubMed ID: 31650290
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Luspatercept as a therapy for myelodysplastic syndromes with ring sideroblasts.
    Schulz F; Nachtkamp K; Kasprzak A; Gattermann N; Haas R; Germing U
    Expert Rev Hematol; 2021 Jun; 14(6):509-516. PubMed ID: 34161752
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Luspatercept in Patients with Lower-Risk Myelodysplastic Syndromes.
    Fenaux P; Platzbecker U; Mufti GJ; Garcia-Manero G; Buckstein R; Santini V; Díez-Campelo M; Finelli C; Cazzola M; Ilhan O; Sekeres MA; Falantes JF; Arrizabalaga B; Salvi F; Giai V; Vyas P; Bowen D; Selleslag D; DeZern AE; Jurcic JG; Germing U; Götze KS; Quesnel B; Beyne-Rauzy O; Cluzeau T; Voso MT; Mazure D; Vellenga E; Greenberg PL; Hellström-Lindberg E; Zeidan AM; Adès L; Verma A; Savona MR; Laadem A; Benzohra A; Zhang J; Rampersad A; Dunshee DR; Linde PG; Sherman ML; Komrokji RS; List AF
    N Engl J Med; 2020 Jan; 382(2):140-151. PubMed ID: 31914241
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment of Anemia in Lower-Risk Myelodysplastic Syndrome.
    Battaglia MR; Cannova J; Madero-Marroquin R; Patel AA
    Curr Treat Options Oncol; 2024 Jun; 25(6):752-768. PubMed ID: 38814537
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Role of Luspatercept in the Management of Lower-Risk Myelodysplastic Syndromes.
    Tinsley-Vance SM; Davis M; Ajayi O
    J Adv Pract Oncol; 2023 Jan; 14(1):82-87. PubMed ID: 36741213
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Luspatercept in the treatment of lower-risk myelodysplastic syndromes.
    Chan O; Komrokji RS
    Future Oncol; 2021 Apr; 17(12):1473-1481. PubMed ID: 33511859
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sotatercept with long-term extension for the treatment of anaemia in patients with lower-risk myelodysplastic syndromes: a phase 2, dose-ranging trial.
    Komrokji R; Garcia-Manero G; Ades L; Prebet T; Steensma DP; Jurcic JG; Sekeres MA; Berdeja J; Savona MR; Beyne-Rauzy O; Stamatoullas A; DeZern AE; Delaunay J; Borthakur G; Rifkin R; Boyd TE; Laadem A; Vo B; Zhang J; Puccio-Pick M; Attie KM; Fenaux P; List AF
    Lancet Haematol; 2018 Feb; 5(2):e63-e72. PubMed ID: 29331635
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of different doses of erythropoietin in patients with myelodysplastic syndromes: A propensity score-matched analysis.
    Balleari E; Filiberti RA; Salvetti C; Allione B; Angelucci E; Bruzzone M; Calzamiglia T; Cavaliere M; Cavalleri M; Cilloni D; Clavio M; Crisà E; Da Col A; Danise P; Pilo F; Ferrero D; Finelli C; Gioia D; Lemoli RM; Masiera E; Messa E; Miglino M; Musto P; Natalie Oliva E; Poloni A; Salvi F; Sanna A; Scudeletti M; Tassara R; Santini V
    Cancer Med; 2019 Dec; 8(18):7567-7576. PubMed ID: 31657156
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Myelodysplastic syndromes with ring sideroblasts.
    Bruzzese A; Vigna E; Martino EA; Mendicino F; Lucia E; Olivito V; Bova C; Barbato A; Filippelli G; Capodanno I; Neri A; Morabito F; Gentile M
    Hematol Oncol; 2023 Oct; 41(4):612-620. PubMed ID: 36794650
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [New treatment for myelodysplastic syndromes: luspatercept and oral hypomethylating agents].
    Usuki K
    Rinsho Ketsueki; 2022; 63(9):1099-1106. PubMed ID: 36198535
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Luspatercept: A Review in Transfusion-Dependent Anaemia due to Myelodysplastic Syndromes or β-Thalassaemia.
    Kang C; Syed YY
    Drugs; 2021 Jun; 81(8):945-952. PubMed ID: 33970460
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adding growth factors or interleukin-3 to erythropoietin has limited effects on anemia of transfusion-dependent patients with myelodysplastic syndromes unresponsive to erythropoietin alone.
    Musto P; Sanpaolo G; D'Arena G; Scalzulli PR; Matera R; Falcone A; Bodenizza C; Perla G; Carotenuto M
    Haematologica; 2001 Jan; 86(1):44-51. PubMed ID: 11146570
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.